iINFLUENCE

Infection in Focus: european network to tackle AMR

Milano
May 6th - 7th, 2026

PROVIDER: Academy Srl ID 707

Sede: Milano

ID ECM: 707-

Crediti ECM:

Ore Formative: 14

Obiettivo Formativo: Tematiche speciali del S.S.N. e/o S.S.R. a carattere urgente e/o straordinario individuate dalla Commissione nazionale per la formazione continua e dalle regioni/province autonome per far fronte a specifiche emergenze sanitarie con acquisizione di nozioni di sistema

Responsabile Scientifico:
D. R. Giacobbe – Dirigente Medico Clinica Malattie Infettive -Ospedale Policlinico San Martino di Genova
A. Vena -Dirigente Medico Clinica Malattie Infettive- Ospedale Policlinico San Martino di Genova

RAZIONALE:

Antimicrobial resistance stands as one of the most urgent global public health concerns of the twenty-first century. Current projections estimate that deaths related to drug-resistant infections could escalate to 10 million by 2050 if proactive measures are not implemented. In intensive care settings the management of infections caused by multidrug-resistant (MDR) Gram-negative bacteria is particularly challenging, posing a significant threat to public health and contributing significantly to both morbidity and mortality. Unfortunately, the current rate of research and development of new antibiotics is insufficient to keep up with the rapid emergence of resistance, and only few new antibiotics have been discovered. In a scenario in which antibiotics may progressively lose their effectiveness, it is essential to gain a deeper understanding of resistance mechanisms, including those affecting newly developed antibiotics, and to implement preventive strategies aimed at limiting the spread of antimicrobial resistance.

In this context, accurate reading and interpretation of the antibiogram are fundamental for the management of complicated infections, particularly in the hospital setting. The antibiogram provides crucial information on pathogen susceptibility to antibiotics, guiding the selection of the most appropriate target therapy. As an essential clinical tool, it reduces reliance on empirical treatment approaches and contributes to antimicrobial stewardship efforts. In fact, therapeutic decision-making depends on several factors, including the pathogen involved, its resistance profile, and the patient's clinical condition.

In light of these considerations, the third edition of iINFLUENCE has established itself as a key reference event for specialists engaged in the fight against bacterial resistance across Europe. Its international setting offers a valuable opportunity for discussion, exchange of experience, and cross-fertilization of ideas, fostering an ideal environment for the development of new clinical and scientific collaborations aimed at combating antimicrobial resistance (AMR).

PROGRAMMA SCIENTIFICO:

May 6th

09:30 – 10:00 Registration

10:00 – 10:10 Welcome and introduction - *D.R. Giacobbe (Italy), A. Vena (Italy)*

Session 1 - Advances in antibiogram interpretation and clinical application

Chairs: M. Colaneri (Italy), D.R. Giacobbe (Italy)

10:10 – 10:40 Phenotypic vs. genotypic antibiograms in Gram-negative bacteria: a round-trip approach – *I. Karaiskos (Greece)*
10:40 – 11:10 Interpretive reading of the phenotypic antibiogram in Gram-positive bacteria – *S. de La Villa (Spain)*
11:10 – 11:30 Discussion of Session 1

Sessione 2 - Frontiers in managing MDR bacterial infections

Chair: A. Gori (Italy)

11:30 – 12:00 From early diagnosis to personalized treatment: innovative strategies in managing Gram-negative infections – *M. Bassetti (Italy)*
12:00 – 12:30 Practice-changing evidence: the landmark studies of 2025 – *P. Muñoz (Spain)*
12:30 – 13:00 Discussion of Session 2

13:00 – 14:00 Lunch break

Session 3 - New antibiotic molecules: innovative therapeutic strategies

Chairs: M. Valerio Minero (Spain), A. Vena (Italy)

14:00 – 14:20 What do new quinolone antibiotics offer our patients? – *A. Vena (Italy)*
14:20 – 14:40 Long-Term therapies for Gram-positive infections: oral treatment or long-acting options? – *M. Valerio Minero (Spain)*
14:40 – 15:00 Current and future role of cefepime including BL/BLi – *D.R. Giacobbe (Italy)*
15:00 – 15:30 Discussion of Session 3

15:30 – 16:00 Coffee break

Session 4 – Public speaking in scientific communication

16:00 – 18:30 Advanced public speaking delivery workshop – *E. Nichols (Italy)*

May 7th

Session 5 - Case-based exploration in Gram-positive and Gram-negative infections: optimizing antibiotic choices

09:30 – 10:30 Workshop *

10:30 – 10:40 *Switch workshop*

10:40 – 11:40 Workshop *

11:40 – 11:50 *Switch workshop*

Session 6 – Comparative insights for the development of an iINFLUENCE network Consensus paper
Chairs: M. Bassetti, D.R. Giacobbe, M. Puoti, J. Salmanton Garcia, A. Vena

11:50 – 13:00 Workshop discussion in plenary room

13:00 – 14:00 *Lunch*

Session 7 - Complex infections in complex patients: is multidisciplinarity the key?
Chairs: *M. Giannella (Italy), L. Escola-Verge (Spain)*

14:00 – 14:40 Hematological patients – *M. Bartoletti (Italy), I. Reinhold (Germany)*
14:40 – 15:20 Intensive care – *L. Ball (Italy), I. Fernández López (Spain)*
15:20 – 16:00 Solid organ transplant – *M. Peghin (Italy), A. Estevez (Spain)*
16:00 – 16:40 Patients with solid tumors – *M. Colaneri (Italy), A. Silva-Pinto (Portugal)*
16:40 – 17:00 Discussion of Session 7

Session 8 - Closing remarks
17:00 – 17:15 iINFLUENCE Network - *D.R. Giacobbe (Italy), A. Vena (Italy)*

17:15 – 17:20 Conclusions and take-home messages - *D.R. Giacobbe (Italy), A. Vena (Italy)*

**(Two clinical cases will be discussed — one involving a Gram-negative bacterial infection and one involving a Gram-positive infection — to determine the most appropriate antibiotic agents for treatment. Open questions will be formulated for working groups (4-5 working groups) to address. Afterwards, a representative from each group will present and discuss the outcomes of their group work in a plenary session. The goal of the workshop is to draft an iINFLUENCE Network position paper for submission to an indexed scientific journal)*

Legenda:

BL/BLi: Beta-lattamico / Inibitore delle beta-lattamasi)
MDR: Multi-Drug Resistant